Improving TRPM3 dysfunction in small nerve fibers and the brain with low-dose naltrexone (LDN) may better explain its clinical efficacy in ME/CFS than solely targeting TRPM3 function in NK cells. The gene discussed is TRPM3; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.